Beyond a decade of 5% imiquimod topical therapy

Journal of Drugs in Dermatology

Volumn 7, Issue 5, 2008, Pages 467-474

  Gaspari, Anthony A ^a   Tyring, Stephen K ^b   Rosen, Theodore ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052938006     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Graceway Pharmaceuticals, LLC. Aldara prescribing information [on-line]. Available at: http://www.aldara.com/pdfs/aldara-ppi.pdf. Accessed October 3, 2008.
2. Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007;79(4 Suppl):36-45.
3. Berman B. Scientific rationale: Combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol. 2008;7(1 Suppl 1):S3-S6.
4. Mayeaux EJ Jr. and Dunton C. Modern management of external genital warts. J Low Genit Tract Dis. 2008;12(3):185-192.
5. McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician. 2007;76(5):667-671.
6. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008;21(2):69-87. (Pubitemid 351628232)
7. Novak N, Yu CF, Bieber T, Allam JP. Toll-like receptor 7 agonists and skin. Drug News Perspect. 2008;21(3):158-165. (Pubitemid 351809139)
8. Schön M, Schön MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem. 2007;14(6):681-687. (Pubitemid 46477720)
9. Schön MP, Schön M. Imiquimod: Mode of action. Br J Dermatol. 2007;157 Suppl 2:8-13. (Pubitemid 350179622)
10. Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27(2):190-199.
11. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008;13(8):859-875.
12. Wagstaff AJ and Perry CM. Topical imiquimod: A review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187-2210. (Pubitemid 47557094)
13. Smith K, Hamza S, Germain M, Skelton H. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatol Surg. 2007;33(12):1419-1428.
14. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-164. (Pubitemid 43023259)
15. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999;191(1):10-19.
16. Thatcher TH, Luzina I, Fishelevich R, et al. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol. 2006;126(4):821-831.
17. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res. 2004;296(1):6-11. (Pubitemid 38828417)
18. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118(1223):U1682.
19. Al-Dujaili Z, Hsu S. Imiquimod-induced vitiligo. Dermatol Online J. 2007;13(2):10.
20. Greenberg HL, Cohen JL, Rosen T, Orendo I. Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes. J Drugs Dermatol. 2007;6(4):452-458.
21. The Centers for Disease Control and Prevention. Available at: http:// www.cdc.gov/std/hpv/default.htm#cancer. Accessed October 22, 2008.
22. The Centers for Disease Control and Prevention. Quadrivalent Human Papillomavirus Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5602a1.htm?s- cid=rr5602a1-e. Accessed February 6, 2009.
23. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/ results?term=gardasil+men. Accessed November 6, 2008.
24. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus- related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23(11):1107-1122. (Pubitemid 41633402)
25. Dede M, Kubar A, Yenen MC, et al. Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. Acta Obstet Gynecol Scand. 2007;86(8):968-972. (Pubitemid 47123597)
26. Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: A randomized, double-blind, placebo-controlled study. J Dermatol. 2004;31(8):627-631. (Pubitemid 39243785)
27. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patientapplied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42(4):789-794. (Pubitemid 28216355)
28. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol. 1998;134(1):25-30.
29. Schöfer H. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. Br J Dermatol. 2007;157 Suppl 2:52-55. (Pubitemid 350179631)
30. Carrasco D, vander Straten M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions. J Am Acad Dermatol. 2002;47(4 Suppl):S212-S216.
31. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: A meta-analysis. Sex Transm Dis. 2008;35(4):346-351. (Pubitemid 351440773)
32. Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis. 2003;30(2):124-128. (Pubitemid 36184359)
33. Audisio T, Roca FC, Piatti C. Topical imiquimod therapy for external anogenital warts in pregnant women. Int J Gynaecol Obstet. 2008;100(3):275-276. (Pubitemid 351258096)
34. Sanclemente G, Herrera S, Tyring SK, et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIVpositive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol. 2007;21(8):1054-1060. (Pubitemid 47304605)
35. Harwood CA, Perrett CM, Brown VL, et al. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol. 2005;152(1):122-129.
36. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795-797. (Pubitemid 18094914)
37. Berhane T, Halliday GM, Cooke B, Barnestson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol. 2002;146(5):810-815. (Pubitemid 34539190)
38. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: How to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335-339.
39. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patientoriented perspective. Arch Dermatol. 1991;127(7):1029-1031.
40. Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16(6):599-606.
41. Cancer Facts and Figures 2008. American Cancer Society. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured. pdf. Accessed October 2, 2008.
42. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547-555. (Pubitemid 39278073)
43. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157(1):133-141. (Pubitemid 46934262)
44. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, doubleblind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57(2):265-268. (Pubitemid 47048863)
45. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, openlabel study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157 Suppl 2:41-46. (Pubitemid 350179629)
46. Graceway Pharmaceuticals, LLC. 1381-IMIQ study data [data on file].
47. Marks R, Gebauer K, Shumack S. A Dose Response Study of Imiquimod For Treatment of Actinic Keratosis. Paper presented at: Winter Clinical Dermatology Conference, 2009; Kohalo Coast, HI.
48. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157 Suppl 2:34-40. (Pubitemid 350179628)
49. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157 Suppl 2:25-31. (Pubitemid 350179626)
50. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: A report of six cases. Br J Dermatol. 2006;155(2):451-454. (Pubitemid 44050583)
51. Ben M'barek L, Mebazaa A, Euvrard S, et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology. 2007;215(5):130-133.
52. Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11(6):195-201.
53. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007;6(8):778-781.
54. Lee S, Selva D, Huilgol SC, et al. Pharmacological treatments for basal cell carcinoma. Drugs. 2007;67(6):915-934. (Pubitemid 46607391)
55. Miller SJ. The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg. 2000;26(3):289-292. (Pubitemid 30146601)
56. Mitropoulos P, Norman R. Nevoid basal cell carcinoma syndrome (Gorlin syndrome): Updated review of minimally invasive treatments. Cutis. 2008;81(1):53-60.
57. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390-398.
58. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: Histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007;6(5):507-513.
59. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: Conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008 ;18(6)677-682.
60. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616-621. (Pubitemid 47384927)
61. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165-1171. (Pubitemid 35025688)
62. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007;6(9):910-914.
63. Tillman DK Jr, Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008;7(1 Suppl 1):S7-S14.
64. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: Preliminary report. J Drugs Dermatol. 2008;7(1 Suppl 1):S15-S16.
65. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/ results?term=imiquimod. Accessed November 5, 2008.
66. Badgwell C, Rosen T. Treatment of limited extent extramammary Paget's disease with 5 percent imiquimod cream. Dermatol Online J. 2006;12(1):22.
67. Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008;58(4):585-591.
68. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275-280.
69. Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis. 1998;178(3):858-861. (Pubitemid 28397238)
70. Grussendorf-Conen EI, Jacobs S, Rubben A, Dethlefsen U. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology. 2002;205(2):139-145.
71. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. 2000;143(5):1026-1031.
72. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol. 2007;56(1):63-68. (Pubitemid 46016997)
73. Lederman ER, Green GM, DeGroot HE, et al. Progressive ORF virus infection in a patient with lymphoma: Successful treatment using imiquimod. Clin Infect Dis. 2007;44(11):E100-E103.
74. Martinez V, Molina JM, Scieux C, et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med. 2006;119(5):E9-E11.
75. Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double-blinded study. Gynecol Oncol. 2007;107(2):219-222. (Pubitemid 47575715)
76. Metcalf S, Crowson AN, Naylor M, et al. Imiquimod as an antiaging agent. J Am Acad Dermatol. 2007;56(3):422-425. (Pubitemid 46273849)
77. Micali G, Dall'Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat. 2003;14(4):233-236. (Pubitemid 37474536)
78. Myhre PE, Levy ML, Eichenfield LF, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol. 2008;25(1):88-95. (Pubitemid 351315460)
79. Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55(2):324-327. (Pubitemid 44038022)
80. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol. 2004;50(5):792-796. (Pubitemid 38580565)
81. Rosen T. Limited extent AIDS-related cutaneous Kaposi's sarcoma responsive to imiquimod 5% cream. Int J Dermatol. 2006;45(7):854-856. (Pubitemid 43984397)
82. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg. 2007;33(4):427-431. (Pubitemid 46570114)
83. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174(3):1259-1268.
84. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis. 2007;195(9):1324-1331. (Pubitemid 46649619)
85. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study. J Infect Dis. 2001;184(2):196-200. (Pubitemid 32614050)
86. Mark K, Spruance S, Kinghorn G, et al. Three phase III randomized controlled trials of topical resiquimod 0.01% to prevent genital herpes recurrences. 17th International Society for Sexually Transmitted Diseases Research Meeting. Seattle, WA; 2007.
87. Bernstein DI, Spruance SL, Arora SS, et al. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: A pilot study. Clin Infect Dis. 2005;41(6):808-814. (Pubitemid 41266746)
88. Cusini M, Salmaso F, Zerboni R, et al. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS. 2004;15(1):17-20. (Pubitemid 38096123)
89. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS. 1999;13(17):2397-2404.
90. Strauss RM, Doyle EL, Mohsen AH, Green ST. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS. 2001;12(4):264-266. (Pubitemid 32291617)
91. Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol. 2006;142(11):1438-1444. (Pubitemid 44790637)
92. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526-1529. (Pubitemid 38314424)
93. Schlaepfer E, Audigé A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol. 2006;176(5):2888-2895.
94. Pockros PJ, Guyader D, Patton H, et al. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, doubleblind phase IIa studies. J Hepatol. 2007;47(2):174-182. (Pubitemid 47021257)
95. Tomai MA, Miller RL, Lipson KE, et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines. 2007;6(5):835-847. (Pubitemid 47607857)
96. Wille-Reece U, Wu CY, Flynn BJ, et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 2005;174(12):7676-7683. (Pubitemid 40806272)
97. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199(6):775-784. (Pubitemid 38375197)